Business Model

Vect-Horus has developed a mixed business model, based on its proprietary VECTrans® technology both to develop an internal pipeline of products and to make its technology platform available to pharmaceutical and biotechnology company partners.
Internal Pipeline: Vect-Horus is building a pipeline of proprietary drug candidates to be developed internally or co-developed with a partner. These products will be developed up to preclinical or early clinical trials and then subsequently out-licensed to pharmaceutical and biotechnology companies. One theragnostic agent RMX-VH-GBM co-developed with RADIOMEDIX is already in clinical trials. .
R&D and licensing agreements with industrial partners: Vect-Horus seeks to develop the broad potential of its proprietary VECTrans® technology platform through research collaborations and licensing agreements in multiple therapeutic applications. The Company is currently involved in a dozen collaborations including three licensing agreements (Novo Nordisk, RadioMedix, etc.).

R&D pipeline

Vect-Horus is leveraging its technology platform to build a pipeline of vector-payload candidates, aiming for indications with strong unmet medical needs such as neurodegenerative diseases, or pathological conditions, including genetic disorders or cancers. The Company has currently the following ongoing collaboration agreements, some of which are still undisclosed.

Strategic Partnerships